Primary vaccinations and boosters effective in reducing COVID-19 severity during Delta and Omicron predominance JAMA_current UNC SARSCoV2 COVID19 Booster PrimaryVaccination Vaccine Delta Omicron Variant
By Dr. Chinta SidharthanSep 29 2022Reviewed by Aimee Molineux In a recent study published in the Journal of the American Medical Association, researchers analyzed coronavirus disease 2019 vaccination and surveillance data to understand the effect of primary vaccinations, boosters, and prior severe acute respiratory syndrome coronavirus 2 infections on severe COVID-19 outcomes and subsequent infections.
About the study In the present study, the researchers analyzed COVID-19 surveillance data from North Carolina between March 2 and June 3, 2022, which contained laboratory-reported polymerase chain reaction and antigen test results, and information on demographics and clinical outcomes. The vaccination history data from December 11, 2020, to June 3, 2022, was procured from the COVID-19 vaccine management system records. The cohort study consisted of data for 10.6 million North Carolina residents.
Related StoriesThe second section of the analysis estimated booster effectivity in individuals with complete primary vaccinations. The waning effect of the booster vaccination on each outcome was calculated by incorporating the time elapsed since the booster vaccination into the analysis. The association of six common combinations of boosters and primary vaccines on COVID-19-related hospitalization and death was analyzed.
Prior SARS-CoV-2 infections reduced the risk of reinfections, hospitalization, and death, but the protective effects diminished with time. Booster vaccines increased protection against infection and severe outcomes in primed individuals with and without previous infections.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study aims to understand how SARS-CoV-2 affects the brain long-termResearchers formulate a method to identify the molecular and systemic factors linking COVID-19 to short- and long-term neurologic illness.
Read more »
Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, primarily causes mild to moderate upper-respiratory tract illness. However, some individuals with COVID-19 develop severe infections and require hospital admission.
Read more »
Q-LAAD: a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2Researchers developed a high-throughput, rapid antigen SARS-CoV-2 spike protein detection test using allonamers, a new type of aptamers that carry out allosteric regulation instead of catalytic activity.
Read more »
Observing SARS-CoV-2 Omicron reinfections with different sub-variantsObserving SARS-CoV-2 Omicron reinfections with different sub-variants SARSCoV2 COVID19 Omicron Reinfection CDCgov
Read more »
COVID-19 cases, hospitalizations, and fatalities prevented by SARS-CoV-2 vaccination within the first 6 months after the vaccine became availableCOVID-19 cases, hospitalizations, and fatalities prevented by SARS-CoV-2 vaccination within the first 6 months after the vaccine became available medrxivpreprint Columbia ColumbiaMSPH COVID19 coronavirus covid vaccination vaccine SARSCoV2
Read more »
SARS-CoV-2 infections linked to increased incidence of new-onset type 1 diabetes in pediatric populationsA new study explored the association of SARS-CoV-2 infection with increased new-onset type 1 diabetes incidences among COVID-19 patients 18 years old and younger.
Read more »